EGFR and neoplasm: When injected into mice harbouring IGFR‘+’/EGFR‘+’ HT-29 tumour xenografts, the di-diabody elicits an anti-tumour response that was statistically similar to that seen in mice treated with a combination of both parent antibodies (Lu et al, 2005).